Core Viewpoint - Tongce Medical's performance shows signs of weakness, with revenue and net profit growth rates below 5%, indicating a lack of robust growth [2][6]. Financial Performance - In the first three quarters of 2025, Tongce Medical achieved revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [1]. - The company's net profit has shown a decline over the past three years, with figures of 515 million yuan, 512 million yuan, and 498 million yuan for the respective periods from 2022 to 2024, reflecting year-on-year decreases of 16.92%, 0.67%, and 2.63% [2]. Historical Context - Tongce Medical, known as "Tooth Ma," has experienced significant growth since its reverse merger in 2007, with revenue and net profit increasing from 91 million yuan and 10 million yuan, respectively [2]. - The company saw a return to high growth in 2021 after a pandemic-related downturn in 2020, with net profit growth rates exceeding 50% [2]. Mergers and Acquisitions - In recent years, Tongce Medical has actively pursued acquisitions, including stakes in multiple dental and medical companies, such as a 50% stake in Hangzhou Qingchun Dental Clinic and a 38.75% stake in Shanghai Sanyue Children's Dental Hospital [3][4]. - The company announced a total transaction amount of 55.41 million yuan for the acquisition of 100% equity and debt of Hangzhou Haiyin Technology Co., Ltd. from its controlling shareholder [4]. Challenges and Market Factors - Despite the acquisitions, they have not yet positively impacted Tongce Medical's operating performance [5]. - The company faces market challenges, including price competition from peers, which has contributed to its sluggish growth [6]. - Research and development investment has stagnated, with figures remaining relatively flat over the past few years, and the gross profit margin has been declining, from 47.96% in 2021 to 41.69% in 2025 [6].